-
JBCRG-14
Phase II study of Letrozole combined with Cyclophosphamide and Capecitabine(LCX) for Hormone-Sensitive advanced breast cancer(age over 65)
- Status
-
Study Closed
- Objectives
-
First: Evaluation of the response rate and the pathological response for primary site , and the safety of Letrozole combined with Cyclophosphamide and Capecitabine (LCX) for Hormone-Sensitive advanced breast cancer(age over 65) . At the same time, the breast-conserving surgery rate, relapse-free survival and overall survival will be assessed. In addition, the clinical efficacy as well as biological properties of the cancer tissue will be investigated using molecular biological and biochemical techniques. Second: Safety,Efficacy
- Subjects
-
- Endpoints
-
First: Overall Response Rate Second: Pathological Complete Response, Safety, Breast Conserving Rate, Disease-free Survival
- Trial Period
-
Oct. 2011～Sep.2018 （Entry：2years, Follow up：5years）
- Lead Principal Investigator
-
Takahiro Nakayama (Department of breast and endocrine surgery, Osaka Medical Center for Cancer and Cardiovascular Disease)
- Target Sample Size
-
32
- Regimen
-
Letrozole, Cyclophosphamide and Capecitabine
- Source of Funding
-
JBCRG(Japan Breast Cancer Research Group)
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
UMIN000006708
- jRCT
-
- Memo
-
- COI Disclosure
-
